Background: Use of collagen membrane (CM) with xenograft and recombinant human platelet‐derived growth factor (rhPDGF) in guided bone regeneration (GBR) is debatable. The aim of this microcomputed tomographic experiment was to assess the efficacy of using PDGF and xenograft (with or without CM) for GBR around immediate implants with dehiscence defects.Methods: Ten beagle dogs underwent atraumatic bilateral second and fourth premolar extractions from both arches. A standardized dehiscence defect (6 × 3 mm) was created on the buccal bone and immediate implants were placed in distal sockets in each site. Animals were randomly divided into three groups: 1) group 1, xenograft with rhPDGF was placed and covered with CM; 2) group 2, xenograft with rhPDGF was placed over the defects; and 3) group 3, four immediate implants were associated with dehiscence (controls). After 16 weeks, animals were sacrificed and jaw segments were assessed for buccal bone thickness (BBT), buccal bone volume (BBV), vertical bone height (VBH), and bone‐to‐implant contact (BIC) using microcomputed tomography.Results: BBT was higher in group 2 (1.533 ± 0.89 mm) than group 1 (0.745 ± 0.322 mm) (P <0.001) and group 3 (0.257 ± 0.232 mm) (P <0.05). BBV was higher in group 2 (67.87 ± 19.83 mm³) than group 1 (42.47 ± 6.78 mm³) (P <0.05) and group 3 (19.12 ± 4.06 mm³) (P <0.001). VBH was higher in group 2 (6.36 ± 1.37 mm) than group 3 (0.00 ± 0.00 mm) (P <0.001). VBH was higher in group 1 (3.91 ± 2.68 mm) than group 3 (0.00 ± 0.00 mm) (P <0.05). BIC was higher in group 2 (67.25% ± 13.42%) than group 1 (36.25% ± 12.78%) (P <0.05) and group 3 (30.25% ± 7.27%) (P <0.01).Conclusion: GBR around immediate implants with dehiscence defects using PDGF and xenograft alone resulted in higher BBT, BBV, VBH, and BIC than when performed in combination with CM.

Objective: This study aimed to investigate and compare potential associations between different COVID-19 vaccines and periodontal diseases, mainly gingival bleeding and oral malodor (bad breath). Materials and methods: This cross-sectional study used an online questionnaire consisting of 15 questions regarding demographic information, medical history, type of COVID-19 vaccine received, history of COVID19, and general and periodontal symptoms after vaccination. The survey was voluntary and privately accessed online using SurveyMonkey (R). A total of 2000 participants from three regions of Saudi Arabia participated in the study from October 11, 2021, to October 11, 2022. Results: Of the participants, 95.8% received at least one dose of the available COVID-19 vaccine. OxfordAstraZeneca was the most administered (41.7%). Patients who suffered from chronic diseases or had a history of COVID-19 infection were less likely to be vaccinated (OR= 0.62, 95% CI 0.40-0.97; OR=0.62, 95% CI 0.39-0.99) compared with people with no chronic diseases or who had a history of COVID-19. The odds ratios for gingival bleeding, oral malodor, mobility, and tooth loss indicated no significant differences regarding vaccination status. Conclusion: COVID-19 vaccines might not affect periodontal tissue conditions. People should not avoid vaccination due to concerns with oral or general health, as the benefits of vaccination outweigh the potential side effects.